Annual report pursuant to Section 13 and 15(d)

NOTE 12 - Stockholders' (Deficiency) Equity

v2.4.0.6
NOTE 12 - Stockholders' (Deficiency) Equity
12 Months Ended
Mar. 31, 2012
Stockholders' Equity Note Disclosure [Text Block]
NOTE 12 — Stockholders’ (Deficiency) Equity

Authorized Capital

The Company is authorized to issue up to 100,000,000 shares of common stock with a par value of $0.0001 per share and 5,000,000 shares of convertible preferred stock with a par value of $0.0001 per share.

Description of Common Stock

Each share of common stock has the right to one vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.

Registered Direct Offering

On December 22, 2011, the Company entered into agreements with institutional and accredited investors to issue 1,809,653 shares of its common stock at $1.15 per share, with no warrant coverage, yielding gross proceeds of $2,081,000 and net proceeds of $1,894,000 after deducting placement agent commissions of $145,000 and other offering costs of $42,000. The offering closed on December 28, 2011.

Common Stock Issued to Non-Employees For Services

On April 24, 2009, the Company entered into an agreement with Advocos LLC, a contract sales organization that serves as part of the Company’s sales force, for the sale of the Company’s wound care products in the United States. Pursuant to the agreement, the Company agreed to pay the contract sales organization a monthly fee and potential bonuses that will be based on achievement of certain levels of sales. The Company agreed to issue the contract sales organization shares of common stock each month as compensation for its services. During the years ended March 31, 2012 and 2011, the Company issued 99,257 and 44,400 shares of common stock, respectively, in connection with this agreement. The Company has determined that the fair value of the common stock, which was calculated as shares were issued, was more readily determinable than the fair value of the services rendered. Accordingly, the Company recorded the fair market value of the stock as compensation expense. During the years ended March 31, 2012 and 2011, the Company recorded $167,000 and $82,000 of stock compensation expense related to this agreement, respectively. The expense was recorded as selling, general and administrative expense in the accompanying consolidated statements of operations.

On December 17, 2009, the Company entered into an agreement with Windsor Corporation.  Windsor Corporation provides financial advisory services to the Company. Pursuant to the agreement, the Company agreed to pay Windsor Corporation, on a quarterly basis, common stock as compensation for services provided.  The Company determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered. Accordingly, the Company recorded the fair market value of the stock as compensation expense. During the years ended March 31, 2012 and 2011, the Company issued 83,146 and 84,354 shares of common stock, respectively.  During the years ended March 31, 2012 and 2011, the Company recorded $135,000 and $156,000, respectively, of stock compensation expense related to this agreement which was recorded as selling, general and administrative expense in the accompanying consolidated statement of operations.

On May 19, 2010, the Company issued common stock to Life Tech Capital, a Division of Aurora Capital, LLC, for providing financial advisory services. The Company agreed to pay Life Tech Capital, a Division of Aurora Capital, LLC, 20,000 shares of common stock for the services provided.  The Company determined the fair value of the common stock was more readily determinable than the fair value of the services rendered. The aggregate fair value of the common stock amounted to $44,000.  Accordingly, during the year ended March 31, 2011, the Company recorded $44,000 of expense related to this agreement which was recorded as selling, general and administrative expense in the accompanying consolidated statement of operations.

On May 19, 2010, the Company issued common stock to Acute Care Partners, Inc., for providing recruiting and other management services. The Company agreed to pay Acute Care Partners, Inc. 50,000 shares of common stock for the services provided.  The Company determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered.  The aggregate fair value of common stock amounted to $111,000.  Accordingly, during the year ended March 31, 2011, the Company recorded $111,000 of expense related to this agreement which was recorded as selling, general and administrative expense in the accompanying consolidated statement of operations.

On September 9, 2010, the Company entered into an agreement with Vista Partners LLC, for providing financial advisory services. Pursuant to the agreement, the Company agreed to pay Vista Partners, LLC common stock as compensation for services provided.  The Company determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered. Accordingly, the Company recorded the fair market value of the stock as compensation expense. During the years ended March 31, 2012 and 2011, the Company issued 85,000 and 55,000 shares of common stock, respectively, in connection with this agreement.  During years ended March 31, 2012 and 2011, the Company recorded $151,000 and $90,000, respectively, of stock compensation expense related to this agreement. The expense was recorded as selling, general and administrative expense in the accompanying condensed consolidated statements of operations.

On April 1, 2011, the Company entered into an agreement with NetGain Financial, Inc., for providing financial advisory services. Pursuant to the agreement, the Company agreed to pay NetGain Financial, Inc. common stock as compensation for services provided.  The Company determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered. Accordingly, the Company recorded the fair market value of the stock as compensation expense. During the year ended March 31, 2012, the Company issued 75,000 shares of common stock in connection with this agreement.  During the year ended March 31, 2012, the Company recorded $133,000 of stock compensation expense related to this agreement. The expense was recorded as selling, general and administrative expense in the accompanying condensed consolidated statements of operations.

Common Stock Purchase Warrants Issued to Service Providers

During the year ended March 31, 2012, the Company issued 90,000 common stock purchase warrants with service conditions. The recorded $42,000 of expense related to the warrants is included as stock compensation expense in the accompanying consolidated statements of operations. The warrants were adjusted to the fair value using the Black Scholes pricing model and the following weighted average assumptions: fair value of the underlying stock of $1.36; risk-free interest rate of 0.94% percent; contractual life of 4.61 years; dividend yield of 0.00%; and vitality of 85.0%.

Common Stock Issued to Settle Obligations

During the year ended March 31, 2011, the Company issued shares of common stock to a vendor to settle outstanding accounts payable. The Company entered into a settlement agreement with this vendor and issued a total of 35,000 shares with a fair value equal to the outstanding payable, or $57,000.

Anti-dilution Adjustments

Pursuant to anti-dilution provisions contained in the August 13, 2007 private placement and in the placement agent warrant agreement, for various financing transactions and common stock issuances the Company is required to adjust the exercise price and the number of warrants held by each warrant holder under these agreements.  Over-time, the exercise price for the warrants has been adjusted from the original exercise price of $9.50 to $4.12.  At March 31, 2012 and 2011, there were 762,876 and 725,866 warrants outstanding that contain this anti-dilution provision, respectively.  The warrants were classified as derivative liabilities in the March 31, 2012 consolidated balance sheet (Note 10).